Document Detail


EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor.
MedLine Citation:
PMID:  19036180     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. METHOD: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). RESULTS: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. CONCLUSION: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors.
Authors:
Esra E Okuyucu; Oguz Guven; Taskin Duman; Sadik Gorur; Ismet M Melek; Soner Akcin; Serkan Yilmazer
Publication Detail:
Type:  Journal Article     Date:  2008-11-25
Journal Detail:
Title:  Neurological research     Volume:  31     ISSN:  0161-6412     ISO Abbreviation:  Neurol. Res.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-05-01     Completed Date:  2009-07-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905298     Medline TA:  Neurol Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  313-5     Citation Subset:  IM    
Affiliation:
Department of Neurology, Mustafa Kemal University, Antakya, Turkey. esraokuyucu@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carbolines / adverse effects*,  therapeutic use
Cohort Studies
Cyclic Nucleotide Phosphodiesterases, Type 5 / antagonists & inhibitors*
Electroencephalography / drug effects*
Erectile Dysfunction / drug therapy*
Humans
Male
Middle Aged
Phosphodiesterase Inhibitors / adverse effects*,  therapeutic use
Time Factors
Chemical
Reg. No./Substance:
0/Carbolines; 0/Phosphodiesterase Inhibitors; 0/tadalafil; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential expression of HSP70 mRNA in the mouse brain after treatment with geldanamycin.
Next Document:  Behavioral model for Homalodisca vitripennis (Hemiptera: Cicadellidae): optimization of host plant u...